|
|
Safety & Watchlist
Reliable picks + red flags
|
|
Safe Pick
|
|
JNJJohnson & Johnson — 64 years of raises and a credit rating the U.S. government can't match
|
|
Band-Aids, Tylenol, surgical tools, cancer drugs — Johnson & Johnson sells health products people buy whether the economy is booming or breaking. In April it raised the dividend 3.1%, to $1.34 a quarter, marking 64 straight years of increases. On a roughly $229 share that's about 2.3%. Here's what earns it the "safe" badge: J&J holds a AAA credit rating — it's one of only two American companies rated that highly, a stronger rating than the U.S. Treasury itself carries. And it pays out about 60% of earnings, a comfortable cushion that lets the raises continue without strain. The honest caveat: this isn't a fast grower — raises have run around 5% a year, and the company still carries talc-lawsuit liabilities that flare up in headlines. But for the steady, sleep-easy core of an income portfolio, few names are sturdier.
|
|
Yield: 2.3%
|
$10K invested = $234/yr
|
Paid: Quarterly
|
|
|
|
Red Flag
|
|
PFEPfizer's 6.6% looks great until you read the second payout ratio
|
|
Pfizer makes the headline-grabbing yield in big pharma right now — about 6.6%, $1.72 a year on a roughly $26 share, with a 350-quarter payment history stretching back to 1937. So why the red flag? Because there are two payout ratios, and they tell opposite stories. On the company's adjusted earnings, the dividend eats about 53%. But on standard GAAP earnings — the audited kind — the payout sits north of 125%, meaning Pfizer paid out more than it actually earned. In 2025 the dividend even ran ahead of free cash flow. The tell I can't ignore: the December raise was a single penny, and the rate's been frozen at $0.43 since. A board that guards a six-decade streak doesn't freeze the raise casually. Analysts expect earnings to keep sliding as old blockbusters lose patent protection. The 6.6% is the market pricing in a possible cut — not a gift. I'd want to see coverage recover before I trusted that check.
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Don't miss this ex-date: American Express goes ex-dividend July 2 — own it before that morning to collect the $0.95 quarterly payment on August 10. Cintas already went ex on May 15, so its next one is the one to watch for in August.
|
|
I ran a screen this morning: low yield, low payout ratio, double-digit raises. Beyond today's AXP and CTAS, the same filter turned up Visa and Mastercard — both paying under 1% but with payout ratios near 20% and decades of room. Quiet compounders hiding behind small headline yields.
|
|
Someone asked me: "Pfizer pays 6.6% and Amex pays 1.1% — isn't Pfizer the better income stock?" Today, yes — $660 a year versus $112 on $10K. But Pfizer's payout is frozen and stretched past 100% of GAAP earnings, while Amex's grows 16% a year. Give it a decade and the gap closes fast. Yield is today's number; growth is tomorrow's.
|
|
|
|
The Dispatch
|
|
Today was about reading past the yield. American Express (16% raise) and Cintas (42 years running) prove a 1% payout can be the better income bet, Johnson & Johnson is the AAA anchor, and Pfizer's 6.6% is the trap to study. Tomorrow's the Weekly Roundup — my single best pick from every section, the whole week in one place. See you then.
|
|
— Charlie
|
|
|
|